These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25512056)

  • 1. Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during 131I-metaiodobenzylguanidine treatment in children with neuroblastoma.
    Clement SC; van Rijn RR; van Eck-Smit BL; van Trotsenburg AS; Caron HN; Tytgat GA; van Santen HM
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):706-15. PubMed ID: 25512056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma.
    van Santen HM; de Kraker J; van Eck BL; de Vijlder JJ; Vulsma T
    Cancer; 2002 Apr; 94(7):2081-9. PubMed ID: 11932913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of the thyroid gland after treatment with 131I-Metaiodobenzylguanidine in children with neuroblastoma: importance of continuous surveillance.
    Clement SC; van Eck-Smit BL; van Trotsenburg AS; Kremer LC; Tytgat GA; van Santen HM
    Pediatr Blood Cancer; 2013 Nov; 60(11):1833-8. PubMed ID: 23832530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma.
    van Santen HM; de Kraker J; van Eck BL; de Vijlder JJ; Vulsma T
    Cancer; 2003 Jul; 98(2):389-96. PubMed ID: 12872361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiated thyroid carcinoma after 131I-MIBG treatment for neuroblastoma during childhood: description of the first two cases.
    van Santen HM; Tytgat GA; van de Wetering MD; van Eck-Smit BL; Hopman SM; van der Steeg AF; Nieveen van Dijkum EJ; van Trotsenburg AS
    Thyroid; 2012 Jun; 22(6):643-6. PubMed ID: 22524499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Thyroid dysfunction due to 131I-metaiodobenzylguanidine in patients with neuroblastoma].
    Garrido Magaña E; Silva Estrada JA; Nishimura Meguro E; Rivera Hernández AJ; Zurita Cruz JN
    Rev Chil Pediatr; 2020 Jun; 91(3):379-384. PubMed ID: 32730518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine late effects from multi-modality treatment of neuroblastoma.
    van Santen HM; de Kraker J; Vulsma T
    Eur J Cancer; 2005 Aug; 41(12):1767-74. PubMed ID: 16039114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine.
    Garaventa A; Gambini C; Villavecchia G; Di Cataldo A; Bertolazzi L; Pizzitola MR; De Bernardi B; Haupt R
    Cancer; 2003 Mar; 97(5):1332-8. PubMed ID: 12599242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking.
    Brans B; Monsieurs M; Laureys G; Kaufman JM; Thierens H; Dierckx RA
    Med Pediatr Oncol; 2002 Jan; 38(1):41-6. PubMed ID: 11835235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.
    Kraal KC; van Dalen EC; Tytgat GA; Van Eck-Smit BL
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010349. PubMed ID: 28429876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
    Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
    J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid function after diagnostic
    Clement SC; Tytgat GAM; van Trotsenburg ASP; Kremer LCM; van Santen HM
    Ann Nucl Med; 2022 Jun; 36(6):579-585. PubMed ID: 35499668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].
    Défachelles AS; Cougnenc O; Carpentier P
    Bull Cancer; 2011 May; 98(5):559-69. PubMed ID: 21609890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
    Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
    J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimated Internal and External Radiation Exposure of Caregivers of Patients With Pediatric Neuroblastoma Undergoing 131I Metaiodobenzylguanidine Therapy: A Prospective Pilot Study.
    Han S; Yoo SH; Koh KN; Lee JJ
    Clin Nucl Med; 2017 Apr; 42(4):271-274. PubMed ID: 28098666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma.
    Picco P; Garaventa A; Claudiani F; Gattorno M; De Bernardi B; Borrone C
    Cancer; 1995 Nov; 76(9):1662-4. PubMed ID: 8635072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.
    Quach A; Ji L; Mishra V; Sznewajs A; Veatch J; Huberty J; Franc B; Sposto R; Groshen S; Wei D; Fitzgerald P; Maris JM; Yanik G; Hawkins RA; Villablanca JG; Matthay KK
    Pediatr Blood Cancer; 2011 Feb; 56(2):191-201. PubMed ID: 20830775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
    Castellani MR; Chiti A; Seregni E; Bombardieri E
    Q J Nucl Med; 2000 Mar; 44(1):77-87. PubMed ID: 10932604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis.
    Bleeker G; Schoot RA; Caron HN; de Kraker J; Hoefnagel CA; van Eck BL; Tytgat GA
    Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1711-7. PubMed ID: 23921531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients.
    Garaventa A; Bellagamba O; Lo Piccolo MS; Milanaccio C; Lanino E; Bertolazzi L; Villavecchia GP; Cabria M; Scopinaro G; Claudiani F; De Bernardi B
    Br J Cancer; 1999 Dec; 81(8):1378-84. PubMed ID: 10604736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.